Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $125.79 +4.58%
EPS Growth %: +1.6%
Financial Fact:
Other income/(expense), net: -1.96M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +1.6%
Financial Fact:
Other income/(expense), net: -1.96M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.
Sees FY17 revenues and EPS at high end of range.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
